LOXL2 and hydrops fetalis: The concept of targeting LOXL2 in HF is supported by our preclinical data from cell-based assays, pharmacological studies and mouse genetic models, as well as by the clinical evidence of elevated cardiac tissue and serum LOXL2 in HF patients and correlation of tissue LOXL2 level with fibrosis and cardiac physiological changes in HF patients.